BioSpace News Archive

Ameresco, Inc. (NYSE:AMRC), a leading cleantech integrator specializing in energy efficiency and renewable energy , today announced that it will release its third quarter 2023 financial results after the close of the market on Monday, November 6, 2023.

Boundless Bio today announced the appointment of two new members to its Board of Directors and the establishment of its Clinical Advisory Board.

Horizon Therapeutics plc Announces New UPLIZNA ® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023.

Lassen Therapeutics presented new preclinical data on LASN01, for treatment of TED, at the American Thyroid Association (ATA) Annual Meeting held in Washington DC, September 27 through October 1, 2023.

UL Solutions Inc. (the “Issuer”) today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) relating to a proposed secondary offering by UL Standards & Engagement, the nonprofit organization that is currently the sole stockholder of the Issuer, of Class A common stock of the Issuer.

The OpenFold group, a non-profit artificial intelligence research consortium of biotech and tech firms whose goal is to develop free and open-source software tools for biology and drug discovery, is announcing the funding of new large-scale protein studies at Prof. Gabriel Rocklin’s laboratory at Northwestern University.

Immunexpress, Pty Ltd. announced a poster presentation demonstrating the usefulness of SeptiCyte® RAPID in conjunction with clinical assessment of sepsis for informing on antibiotic administration and bundle compliance at the annual meeting of the American College of Chest Physicians.

MEI Pharma, Inc. announced that its Board of Directors has unanimously approved the adoption of a limited-duration stockholder rights plan under which stockholders will receive rights to purchase a new series of preferred stock in certain circumstances.

AntiCancer Inc. of San Diego has announced its PDOX mouse model of human cancer patients has demonstrated high concordance of chemotherapy in the mouse and patient.